306 related articles for article (PubMed ID: 37415134)
1. Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages.
He W; Huang Y; Shi X; Wang Q; Wu M; Li H; Liu Q; Zhang X; Huang C; Li X
J Transl Med; 2023 Jul; 21(1):448. PubMed ID: 37415134
[TBL] [Abstract][Full Text] [Related]
2. Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis.
He W; Huang C; Zhang X; Wang D; Chen Y; Zhao Y; Li X
Endocrine; 2021 Jul; 73(1):52-64. PubMed ID: 33837926
[TBL] [Abstract][Full Text] [Related]
3. Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
Qing J; Ren Y; Zhang Y; Yan M; Zhang H; Wu D; Ma Y; Chen Y; Huang X; Wu Q; Mazhar M; Wang L; Liu J; Ding BS; Cao Z
J Hepatol; 2022 Feb; 76(2):394-406. PubMed ID: 34648896
[TBL] [Abstract][Full Text] [Related]
4. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
5. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
Peiseler M; Schwabe R; Hampe J; Kubes P; Heikenwälder M; Tacke F
J Hepatol; 2022 Oct; 77(4):1136-1160. PubMed ID: 35750137
[TBL] [Abstract][Full Text] [Related]
6. [Macrophage heterogeneity role in NAFLD and NASH disease progression].
Yang T; Wang X; Jiang LF; Li J
Zhonghua Gan Zang Bing Za Zhi; 2023 Jul; 31(7):770-775. PubMed ID: 37580264
[TBL] [Abstract][Full Text] [Related]
7. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
[TBL] [Abstract][Full Text] [Related]
8. STING expression in monocyte-derived macrophages is associated with the progression of liver inflammation and fibrosis in patients with nonalcoholic fatty liver disease.
Wang X; Rao H; Zhao J; Wee A; Li X; Fei R; Huang R; Wu C; Liu F; Wei L
Lab Invest; 2020 Apr; 100(4):542-552. PubMed ID: 31745210
[TBL] [Abstract][Full Text] [Related]
9. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
10. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
11. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
[TBL] [Abstract][Full Text] [Related]
12. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease.
Jiao J; Sanchez JI; Saldarriaga OA; Solis LM; Tweardy DJ; Maru DM; Stevenson HL; Beretta L
JHEP Rep; 2023 Feb; 5(2):100628. PubMed ID: 36687470
[TBL] [Abstract][Full Text] [Related]
13. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
[TBL] [Abstract][Full Text] [Related]
14. Macrophage functional diversity in NAFLD - more than inflammation.
Barreby E; Chen P; Aouadi M
Nat Rev Endocrinol; 2022 Aug; 18(8):461-472. PubMed ID: 35534573
[TBL] [Abstract][Full Text] [Related]
15. Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis.
Magee N; Ahamed F; Eppler N; Jones E; Ghosh P; He L; Zhang Y
Liver Res; 2022 Dec; 6(4):238-250. PubMed ID: 36864891
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD.
Pantano L; Agyapong G; Shen Y; Zhuo Z; Fernandez-Albert F; Rust W; Knebel D; Hill J; Boustany-Kari CM; Doerner JF; Rippmann JF; Chung RT; Ho Sui SJ; Simon E; Corey KE
Sci Rep; 2021 Sep; 11(1):18045. PubMed ID: 34508113
[TBL] [Abstract][Full Text] [Related]
18. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
19. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
20. The macrophage-associated microRNA-4715-3p / Gasdermin D axis potentially indicates fibrosis progression in nonalcoholic fatty liver disease: evidence from transcriptome and biological data.
Chen S; Cai X; Liu Y; Shen Y; Guillot A; Tacke F; Tang L; Liu H
Bioengineered; 2022 May; 13(5):11740-11751. PubMed ID: 35521691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
